I
Inmaculada de la Torre
Researcher at Eli Lilly and Company
Publications - 72
Citations - 1989
Inmaculada de la Torre is an academic researcher from Eli Lilly and Company. The author has contributed to research in topics: Rheumatoid arthritis & Medicine. The author has an hindex of 17, co-authored 63 publications receiving 1275 citations. Previous affiliations of Inmaculada de la Torre include University College London & Hospital General Universitario Gregorio Marañón.
Papers
More filters
Journal ArticleDOI
B-cell-activating factor receptor expression on naive and memory B cells: relationship with relapse in patients with rheumatoid arthritis following B-cell depletion therapy
Inmaculada de la Torre,Rita A Moura,Maria J. Leandro,Jonathan C. W. Edwards,Geraldine Cambridge +4 more
TL;DR: BAFF-R expression was significantly reduced on both naive and memory B cells in patients at relapse, regardless of the relationship with B-cell repopulation or serum BAFF levels.
Journal Article
The effect of JAK1/JAK2 inhibition in rheumatoid arthritis: efficacy and safety of baricitinib.
Ernest Choy,C. Miceli-Richard,Miguel A. González-Gay,Luigi Sinigaglia,Douglas E Schlichting,Gabriella Meszaros,Inmaculada de la Torre,Hendrik Schulze-Koops +7 more
TL;DR: A narrative review focuses on the clinical efficacy and safety of baricitinib, but also provides an overview of its mechanism of action in relation to JAK1/JAK2 signalling and discusses the possible clinical implications in patients with RA.
Journal ArticleDOI
Multicentre, randomised, open-label, parallel-group study evaluating the efficacy and safety of ixekizumab versus adalimumab in patients with psoriatic arthritis naïve to biological disease-modifying antirheumatic drug: final results by week 52
Josef S Smolen,Philip J. Mease,Hasan Tahir,Hendrik Schulze-Koops,Inmaculada de la Torre,Lingnan Li,M. Hojnik,Christophe Sapin,Masato Okada,Roberto Caporali,Jordi Gratacós,Philippe Goupille,Soyi Liu Leage,Sreekumar G. Pillai,Peter Nash +14 more
TL;DR: IXE provided significantly greater simultaneous joint and skin improvement than ADA through Wk52 in bionaïve patients with PsA and showed better efficacy on psoriasis and performed at least as well as ADA on musculoskeletal manifestations.
Journal ArticleDOI
Effect of Baricitinib and Adalimumab in Reducing Pain and Improving Function in Patients with Rheumatoid Arthritis in Low Disease Activity: Exploratory Analyses from RA-BEAM.
Bruno Fautrel,Bruce Kirkham,Janet E. Pope,Tsutomu Takeuchi,Carol L. Gaich,Amanda Quebe,B Zhu,Inmaculada de la Torre,Francesco De Leonardis,Peter C. Taylor +9 more
TL;DR: Baricitinib 4 mg once daily provided enhanced improvement in pain and physical function in patients with well-controlled RA, suggesting it may produce effects beyond immunomodulation.
Journal ArticleDOI
Patient self-assessment and physician’s assessment of rheumatoid arthritis activity: which is more realistic in remission status? A comparison with ultrasonography
Iustina Janta,Esperanza Naredo,Lina Martínez-Estupiñán,Juan Carlos Nieto,Inmaculada de la Torre,Lara Valor,Lidia Estopiñán,N. Bello,M. Hinojosa,Carlos M. González,Javier López-Longo,Indalecio Monteagudo,María Montoro,Luis Carreño +13 more
TL;DR: Patient self-assessment overestimated disease activity determined by the DAS28 and physician-assessed joint swelling showed an acceptable concordance with Doppler US synovitis.